Novel Nanoparticle Platform for the delivery of Vaccines and Adjuvants
用于输送疫苗和佐剂的新型纳米颗粒平台
基本信息
- 批准号:9229872
- 负责人:
- 金额:$ 13.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-01 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcademiaAdjuvantAnimal ModelApplications GrantsBiotechnologyChemistryDengue VirusDoseFDA approvedFormulationGoalsHumanImmune responseImmune systemImmunityImmunologyIndustryInstructionMedicalMoldsMolecularMusNanotechnologyNorth CarolinaPatternPorosityProcessPropertyPublic HealthShapesSystemTechnologyTestingTranslationsUniversitiesVaccine AdjuvantVaccinesVirusVirus Diseasesantiviral immunitybaseflexibilityhumanized mouseinfluenzaviruslithographymaterials sciencemicrobialnanoparticlenovelparticlepathogenvaccine deliveryvirology
项目摘要
The overarching purpose of this U19 Center grant application is to optimize a novel nanoparticle (NP)
platform for the delivery of vaccines and vaccine adjuvants. The application is cross-disciplinary and requires
expertise in material sciences, immunology, virology and animal models. We will test this platform for two
viruses of high-medical need: influenza and Dengue virus. Once optimized, this platform should be
adaptable for the delivery of vaccines against a variety of microbial pathogens. The NP technology platform
is distinguished by the application of a soft lithography particle molding process called Particle Replication In
Non-wetting Templates (PRINT) to produce the particles. This technology was developed by Dr. Joseph
DeSimone at the University of North Carolina, who also founded the biotechnology company, Liquidia
Technologies. A major advantage of PRINT is that the NPs produced are immunologically-inert and are of
precise size, chemistry, porosity, flexibility and shape. Importantly, GMP (Good Manufacturing Practices)
quality PRINT-NPs can be fabricated in large quantities by our industrial partner, Liquidia. A standard
PRINT-NP has been used to deliver FDA-approved vaccines, with preliminary results demonstrating that this
delivery system enhanced immunity compared to soluble vaccine and further provided a dose-sparing effect.
This application has three projects based at UNC, supported by four cores that include industry-academia
partnerships. All three projects are highly inter-related and have the ultimate goal of enabling an eventual
IND application for optimized vaccine/adjuvant biologics. The first project will optimize the PRINT-NP
chemistries to enhance biologic efficacy as a vaccine delivery system. The second project will focus on the
co-delivery of PAMPs (Pathogen-associated Molecular Patterns) as adjuvants to stimulate anti-viral immunity
in mice and appropriate larger animal models. The third project will use a novel humanized mouse system to
assess human immune responses to NP-delivered vaccine and adjuvant. The three projects are highly
integrated to discover the most optimal PRINT-NP platform needed for vaccine and adjuvant delivery for
translation in humans.
U19中心资助申请的首要目的是优化一种新型纳米颗粒(NP)。
疫苗和疫苗佐剂的输送平台。该应用程序是跨学科的,需要
在材料科学、免疫学、病毒学和动物模型方面的专业知识。我们将测试两个平台
高医疗需求的病毒:流感和登革热病毒。一旦优化,该平台应
适于递送针对多种微生物病原体的疫苗。NP技术平台
其特点是应用了一种称为颗粒复制的软光刻颗粒成型工艺,
非润湿模板(PRINT)生产颗粒。这项技术是由约瑟夫博士
北卡罗来纳州大学的DeSimone也创立了生物技术公司Liquidia
技术. PRINT的一个主要优点是产生的NP是免疫惰性的,并且具有免疫原性。
精确的尺寸、化学性质、多孔性、柔韧性和形状。GMP(Good Manufacturing Practices)
我们的工业合作伙伴Liquidia可以大批量生产高质量的PRINT-NP。标准
PRINT-NP已用于递送FDA批准的疫苗,初步结果表明,
与可溶性疫苗相比,递送系统增强了免疫力,并进一步提供了剂量节省效应。
这个应用程序有三个基于IBM的项目,由四个核心支持,包括工业和学术界
伙伴关系。所有这三个项目都是高度相关的,其最终目标是实现一个最终的
优化疫苗/佐剂生物制剂的IND申请。第一个项目将优化PRINT-NP
作为疫苗递送系统,化学物质增强生物功效。第二个项目将侧重于
共递送PAMP(病原体相关分子模式)作为佐剂以刺激抗病毒免疫
在小鼠和适当的大型动物模型中。第三个项目将使用一种新颖的人性化鼠标系统,
评估人对NP递送的疫苗和佐剂的免疫应答。这三个项目高度
整合以发现疫苗和佐剂递送所需的最佳PRINT-NP平台,
翻译人类
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jenny P Ting其他文献
Jenny P Ting的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jenny P Ting', 18)}}的其他基金
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
细胞内先天免疫受体在癌症抑制和免疫治疗中的作用
- 批准号:
10654660 - 财政年份:2019
- 资助金额:
$ 13.23万 - 项目类别:
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
细胞内先天免疫受体在癌症抑制和免疫治疗中的作用
- 批准号:
10451800 - 财政年份:2019
- 资助金额:
$ 13.23万 - 项目类别:
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
细胞内先天免疫受体在癌症抑制和免疫治疗中的作用
- 批准号:
10217045 - 财政年份:2019
- 资助金额:
$ 13.23万 - 项目类别:
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
细胞内先天免疫受体在癌症抑制和免疫治疗中的作用
- 批准号:
10019472 - 财政年份:2019
- 资助金额:
$ 13.23万 - 项目类别:
Novel Nanoparticle Platform for the delivery of Vaccines and Adjuvants
用于输送疫苗和佐剂的新型纳米颗粒平台
- 批准号:
8642227 - 财政年份:2014
- 资助金额:
$ 13.23万 - 项目类别:
Engineering Monodisperse Particulate Vaccines to Tailor Immunological Responses
设计单分散颗粒疫苗以定制免疫反应
- 批准号:
9337971 - 财政年份:2014
- 资助金额:
$ 13.23万 - 项目类别:
Discovery of New Innate Immune Pathways in Viral Recognition
病毒识别中新先天免疫途径的发现
- 批准号:
8653231 - 财政年份:2014
- 资助金额:
$ 13.23万 - 项目类别:
Novel Nanoparticle Platform for the delivery of Vaccines and Adjuvants
用于输送疫苗和佐剂的新型纳米颗粒平台
- 批准号:
9307701 - 财政年份:2014
- 资助金额:
$ 13.23万 - 项目类别:
Novel Nucleic Acid Sensing NLRs and Innate Immunity to Viruses
新型核酸传感 NLR 和病毒先天免疫
- 批准号:
9233910 - 财政年份:2014
- 资助金额:
$ 13.23万 - 项目类别:
NOD-like Receptors in Intestinal Inflammation
肠道炎症中的 NOD 样受体
- 批准号:
10447741 - 财政年份:2013
- 资助金额:
$ 13.23万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别: